Hospital
Georgetown Community Hospital LLC
Georgetown Community Hospital LLC was paid $44.03M by Medicaid between Jan 2018 and Dec 2024, across 267 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoGEORGETOWN COMMUNITY HOSPITAL LLC
GEORGETOWN, KY 40324
GEORGETOWN, KY 40324
33aNPI1326107319assigned 12/06/2006
33bProvider typeRural Acute Care Hospital
28Total paid$44.03M
24GClaims796,831
24DCodes billed267
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Kentucky
Rank by total paid#5 of 10
Median peer was paid$23.35M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 105,733 | $6.31M | |
| 2019 | 97,456 | $5.25M | |
| 2020 | 103,487 | $4.94M | |
| 2021 | 123,893 | $6.04M | |
| 2022 | 129,449 | $6.54M | |
| 2023 | 134,616 | $7.84M | |
| 2024incomplete | 102,197 | $7.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 27,359 | 21,993 | $6.70M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 30,806 | 26,037 | $4.73M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.9% | 6,935 | 5,558 | $4.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 7,958 | 5,641 | $2.59M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.2% | 7,011 | 6,313 | $2.30M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.3% | 3,317 | 2,661 | $1.90M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.3% | 15,164 | 13,698 | $1.46M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 13,403 | 10,055 | $1.25M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 5,488 | 4,075 | $1.07M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 3,471 | 2,685 | $935K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 15,745 | 12,747 | $934K |
| G0378 | Hospital observation service, per hour | 2.1% | 2,458 | 1,709 | $934K |
255 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 7,195 | $679K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 13,439 | $665K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.5% | 14,587 | $660K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 10,373 | $643K |
| 80053 | Comprehensive metabolic panel | 1.2% | 59,392 | $547K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 1,250 | $543K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 11,706 | $516K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 7,516 | $478K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.0% | 10,868 | $459K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,881 | $433K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,570 | $387K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,523 | $333K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 343 | $300K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,625 | $250K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,215 | $243K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,055 | $236K |
| 87486 | <1% | 9,886 | $206K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,338 | $186K |
| 87581 | <1% | 6,977 | $186K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 7,067 | $184K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 819 | $183K |
| 73562 | <1% | 2,574 | $182K | |
| 72100 | <1% | 1,929 | $181K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,309 | $168K |
| 73630 | <1% | 2,277 | $161K | |
| 74018 | <1% | 2,767 | $157K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,335 | $151K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,910 | $149K |
| 72131 | <1% | 574 | $144K | |
| 73610 | <1% | 2,075 | $144K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,867 | $141K |
| J2704 | Injection, propofol, 10 mg | <1% | 9,256 | $135K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 295 | $133K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,513 | $133K |
| 73130 | <1% | 1,933 | $124K | |
| 73030 | <1% | 1,943 | $118K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,763 | $118K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,584 | $116K |
| 84484 | <1% | 9,780 | $108K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 231 | $102K |
| 96376 | <1% | 2,745 | $102K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,846 | $99K |
| 93971 | <1% | 613 | $99K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,708 | $98K |
| 71250 | <1% | 460 | $90K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,975 | $88K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,789 | $83K |
| 81025 | <1% | 8,060 | $77K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,380 | $75K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 115 | $73K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,621 | $72K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 267 | $70K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 185 | $70K |
| 73110 | <1% | 1,129 | $68K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,755 | $68K |
| 83690 | <1% | 12,584 | $68K | |
| 81001 | <1% | 21,577 | $67K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,677 | $61K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,858 | $59K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,024 | $59K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,875 | $55K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,615 | $54K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,983 | $47K |
| 86677 | <1% | 1,340 | $46K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,426 | $44K |
| 85027 | <1% | 7,006 | $43K | |
| 83970 | <1% | 1,258 | $43K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 187 | $43K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,810 | $41K |
| 87070 | <1% | 5,518 | $40K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,214 | $39K |
| 82728 | <1% | 3,323 | $38K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,861 | $36K |
| 93017 | <1% | 213 | $35K | |
| 83735 | <1% | 6,956 | $35K | |
| 82962 | <1% | 6,484 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,616 | $34K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,864 | $34K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,776 | $33K |
| 90715 | <1% | 1,024 | $33K | |
| 80061 | Lipid panel | <1% | 3,059 | $31K |
| 82746 | <1% | 2,648 | $31K | |
| 97162 | <1% | 1,072 | $31K | |
| 70486 | <1% | 133 | $31K | |
| 83921 | <1% | 1,859 | $31K | |
| 83880 | <1% | 1,323 | $31K | |
| 87522 | Neg quan hep c or qual rna | <1% | 727 | $31K |
| 84425 | <1% | 1,696 | $30K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,373 | $30K |
| 76830 | Ultrasound, transvaginal | <1% | 173 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,160 | $29K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 10,020 | $29K |
| 83605 | <1% | 3,340 | $28K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,036 | $26K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,807 | $26K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 26 | $26K |
| 87507 | <1% | 106 | $25K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,547 | $25K |
| 72040 | <1% | 327 | $25K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 723 | $24K |
| 85610 | <1% | 7,575 | $24K | |
| 84703 | <1% | 3,670 | $23K | |
| 70498 | <1% | 57 | $22K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 765 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 745 | $21K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 408 | $21K |
| 87040 | <1% | 1,713 | $20K | |
| 84145 | <1% | 1,130 | $20K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,344 | $19K |
| 87186 | <1% | 2,780 | $19K | |
| 87077 | <1% | 3,470 | $19K | |
| 83540 | <1% | 3,240 | $17K | |
| 85379 | <1% | 2,233 | $17K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 888 | $17K |
| 20610 | <1% | 85 | $16K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,453 | $16K |
| 84446 | <1% | 1,401 | $16K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,579 | $16K |
| 84134 | <1% | 1,274 | $16K | |
| 97533 | <1% | 780 | $15K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 848 | $14K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,598 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 873 | $14K |
| 73080 | <1% | 208 | $14K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 251 | $13K |
| 73502 | <1% | 244 | $13K | |
| 82607 | <1% | 1,125 | $13K | |
| 84590 | <1% | 1,415 | $13K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,676 | $13K |
| 29125 | <1% | 181 | $12K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 66 | $12K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,944 | $12K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 555 | $12K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 953 | $12K |
| 85730 | <1% | 2,903 | $12K | |
| 84702 | <1% | 961 | $11K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 815 | $11K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 33 | $11K |
| 76642 | <1% | 120 | $11K | |
| 83550 | <1% | 1,545 | $11K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 809 | $10K |
| 86140 | <1% | 2,527 | $10K | |
| 70496 | <1% | 30 | $10K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 642 | $10K |
| 12001 | <1% | 111 | $10K | |
| 84439 | <1% | 1,049 | $9K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 51 | $9K |
| 94760 | <1% | 237 | $8K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 89 | $8K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 61 | $8K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $7K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 60 | $7K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 147 | $7K |
| 84100 | <1% | 1,932 | $7K | |
| 73590 | <1% | 123 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 133 | $7K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,063 | $7K |
| 97161 | <1% | 183 | $6K | |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 520 | $6K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $6K |
| 62323 | <1% | 18 | $5K | |
| 86850 | <1% | 759 | $5K | |
| 72141 | <1% | 14 | $5K | |
| 73090 | <1% | 82 | $5K | |
| 87902 | <1% | 15 | $5K | |
| 85652 | <1% | 2,034 | $4K | |
| 80074 | <1% | 132 | $4K | |
| 87420 | <1% | 383 | $4K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 69 | $4K |
| 86706 | <1% | 380 | $4K | |
| J1815 | Injection, insulin, per 5 units | <1% | 112 | $4K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 228 | $4K |
| 86900 | <1% | 1,470 | $4K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 196 | $4K |
| 86901 | <1% | 1,456 | $4K | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 54 | $3K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 379 | $3K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 274 | $3K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 14 | $3K |
| 73140 | <1% | 43 | $3K | |
| 82550 | <1% | 586 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 600 | $3K |
| 87340 | <1% | 282 | $3K | |
| J3490 | Unclassified drugs | <1% | 1,009 | $3K |
| 74240 | <1% | 15 | $3K | |
| 86704 | <1% | 253 | $3K | |
| 36416 | <1% | 186 | $3K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 144 | $2K |
| 87900 | <1% | 15 | $2K | |
| 86705 | <1% | 209 | $2K | |
| 82565 | <1% | 132 | $2K | |
| 82248 | <1% | 396 | $2K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 16 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 253 | $2K |
| 64488 | <1% | 16 | $2K | |
| 10060 | <1% | 27 | $2K | |
| C9399 | Unclassified drugs or biologicals | <1% | 55 | $2K |
| 86708 | <1% | 139 | $2K | |
| 76536 | <1% | 12 | $2K | |
| 82172 | <1% | 89 | $2K | |
| 94060 | <1% | 16 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 39 | $1K |
| 20553 | <1% | 24 | $1K | |
| 92609 | <1% | 71 | $1K | |
| 71271 | <1% | 66 | $1K | |
| 94729 | <1% | 36 | $1K | |
| 83010 | <1% | 91 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 67 | $1K |
| 71101 | <1% | 17 | $1K | |
| 82784 | <1% | 144 | $1K | |
| 82977 | <1% | 137 | $1K | |
| 83615 | <1% | 196 | $1K | |
| 74019 | <1% | 12 | $999.88 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 71 | $935.02 |
| 87220 | <1% | 198 | $922.26 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 56 | $872.20 |
| 94726 | <1% | 30 | $821.08 | |
| 87210 | <1% | 185 | $807.87 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 50 | $806.29 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 18 | $747.87 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 69 | $738.63 |
| 97165 | <1% | 30 | $716.53 | |
| 97116 | <1% | 36 | $681.91 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 63 | $662.44 |
| 82247 | <1% | 140 | $654.89 | |
| 92523 | <1% | 12 | $600.49 | |
| 84460 | <1% | 119 | $590.30 | |
| 80069 | <1% | 50 | $549.65 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 47 | $516.37 |
| 82785 | <1% | 31 | $493.76 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 45 | $474.99 |
| 84550 | <1% | 68 | $426.24 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 199 | $378.17 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $355.16 |
| 82570 | <1% | 40 | $317.36 | |
| 84153 | <1% | 27 | $262.85 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 38 | $252.10 |
| 84436 | <1% | 48 | $247.17 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 19 | $238.39 |
| 83516 | <1% | 14 | $219.74 | |
| 82104 | <1% | 12 | $207.64 | |
| 82103 | <1% | 12 | $202.10 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 35 | $167.04 |
| 86038 | <1% | 14 | $165.72 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $153.73 |
| 80076 | <1% | 16 | $132.70 | |
| 99406 | <1% | 16 | $130.11 | |
| 82553 | <1% | 12 | $128.02 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 152 | $112.93 |
| 84479 | <1% | 17 | $59.14 | |
| 84156 | <1% | 19 | $50.15 | |
| 82009 | <1% | 13 | $45.01 | |
| 85014 | <1% | 18 | $23.34 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $17.74 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 65 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.